Status:
UNKNOWN
Long Covid After COVID-19 Infection With Omicron Variant
Lead Sponsor:
Faroese Hospital System
Collaborating Sponsors:
Chief Medical Officer's Office Faroe Islands
University of the Faroe Islands
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
The COVID-19 pandemic has led to a high disease burden worldwide, both during the acute disease phase and a large group of infected suffering from Long Covid. Long Covid has been subject to a lot of r...
Detailed Description
Objectives Primary objective: To investigate Long Covid symptoms after Omicron infection through monthly surveys for six months, compared to controls not infected. Secondary objective: To investigate...
Eligibility Criteria
Inclusion
- Inclusion Criteria Cases:
- Confirmed COVID-19 during January 2022 in the Faroe Islands.
- Exclusion Criteria Cases:
- Not reachable
- Inclusion Criteria Controls:
- Participant in serological survey amongst random sample of Faroese inhabitants in 2020
- Exclusion Criteria Cases:
- Confirmed COVID-19 during December 2021 or January 2022
Exclusion
Key Trial Info
Start Date :
January 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 7 2022
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT05234294
Start Date
January 31 2022
End Date
August 7 2022
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Faroses Hospital System
Tórshavn, Faroe Islands, 100